{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:26:22Z","timestamp":1794108382835,"version":"4.8.0"},"reference-count":49,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.1021\/acs.molpharmaceut.2c00666","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T13:22:25Z","timestamp":1668432145000},"page":"357-369","source":"Crossref","is-referenced-by-count":8,"title":["Dynamic Changes in Gastrointestinal Fluid Characteristics after Food Ingestion Are Important for Quantitatively Predicting the <i>In Vivo<\/i> Performance of Oral Solid Dosage Forms in Humans in the Fed State"],"prefix":"10.1021","volume":"20","author":[{"given":"Tsuyoshi","family":"Kiyota","sequence":"first","affiliation":[{"name":"Pharmaceutical Research and Technology Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka425-0072, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research and Technology Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka425-0072, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6287","authenticated-orcid":true,"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research and Technology Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Shizuoka425-0072, Japan"},{"name":"School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka422-8526, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"ref1\/cit1","unstructured":"US\nFood and Drug Administration. Guidance for Industry:\nFood-Effect Bioavailability and Fed Bioequivalence Studies, 2002."},{"key":"ref2\/cit2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.255"},{"key":"ref3\/cit3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.3285"},{"key":"ref4\/cit4","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.115"},{"key":"ref5\/cit5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0440-1"},{"key":"ref6\/cit6","unstructured":"US\nFood and Drug Administration. Prescribing Information\nof TYKERB. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022059s007lbl.pdf (accessed 2021\u201309\u201323)."},{"key":"ref7\/cit7","unstructured":"US\nFood and Drug Administration. Prescribing Information\nof MEKINIST. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204114s007lbl.pdf (accessed 2021\u201309\u201323)."},{"key":"ref8\/cit8","unstructured":"US\nFood and Drug Administration. Prescribing Information\nof GILOTRIF. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/201292s014lbl.pdf (accessed 2021\u201309\u201323)."},{"key":"ref9\/cit9","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9025-8"},{"key":"ref10\/cit10","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00463-y"},{"key":"ref11\/cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105554"},{"key":"ref12\/cit12","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00511-7"},{"key":"ref13\/cit13","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00601-0"},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00778"},{"key":"ref15\/cit15","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on Gleevec. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21-335_Gleevec_biopharmr_P2.pdf (accessed 2021\u201310\u201328)."},{"key":"ref16\/cit16","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1000"},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23519"},{"key":"ref18\/cit18","unstructured":"Pharmaceuticals\nand Medical Devices Agency. Clinical Summary of New\nDrug Application: JAKAVI Tablets. https:\/\/www.pmda.go.jp\/drugs\/2014\/P201400093\/index.html (accessed 2021\u201309\u201325)."},{"key":"ref19\/cit19","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.208"},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.5599\/admet.4.4.338"},{"key":"ref21\/cit21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S249098"},{"key":"ref22\/cit22","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on TAFINLAR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/202806orig1s000clinpharmr.pdf (accessed 2021\u201309\u201325)."},{"key":"ref23\/cit23","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on Ruxolitinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202192Orig1s000ClinPharmR.pdf (accessed 2021\u201309\u201325)."},{"key":"ref24\/cit24","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on Tasigna. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022068s000_ClinPharmR.pdf (accessed 2021\u201309\u201325)."},{"key":"ref25\/cit25","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on TYKERB. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022059s000_ClinPharmR.pdf (accessed 2021\u201309\u201325)."},{"key":"ref26\/cit26","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9569-4"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.03.020"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.11.008"},{"key":"ref29\/cit29","unstructured":"US\nFood and Drug Administration. Guidance for Industry:\nUse of Liquids and\/or Soft Foods as Vehicles for Drug Administration:\nGeneral Considerations for Selection and In Vitro Methods for Product\nQuality Assessments. https:\/\/www.fda.gov\/media\/114872\/download (accessed 2022\u201301\u201321)"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02683.x"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.03.002"},{"key":"ref32\/cit32","volume-title":"Biopharmaceutics of Orally Administered Drugs","author":"Macheras P.","year":"1995"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1021\/mp500210c"},{"key":"ref34\/cit34","unstructured":"Pharmaceuticals and Medical Devices Agency. Clinical\nSummary of New Drug Application: LORBRENA Tablets. https:\/\/www.pmda.go.jp\/drugs\/2018\/P20181019001\/index.html (accessed 2021\u201309\u201325)."},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.127"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0162-4"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1821"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018911728161"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.04.005"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.05.015"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-10-RG-098"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010927026837"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.10.055"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262101"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.08.008"},{"key":"ref46\/cit46","unstructured":"US\nFood and Drug Administration. Clinical Pharmacology\nand Biopharmaceutics Review on Myrbetriq. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202611Orig1s000ClinPharmR.pdf (accessed 2021\u201310\u201328)."},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105535"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.04.008"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.11.058"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.2c00666","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.2c00666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:58:25Z","timestamp":1682603905000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.2c00666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,2]]}},"alternative-id":["10.1021\/acs.molpharmaceut.2c00666"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00666","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}